Steven Hamilton, PhD, MD

RESEARCH UPDATE

Mirtazapine and B6 Outperform Propranolol for Akathisia

June 1, 2025

Steven Hamilton, PhD, MD.

Dr. Hamilton has no financial relationships with companies related to this material.

Researchers compares treatments for antipsychotic-induced akathisia, highlighting options that may offer relief with fewer side effects.

Clinical Update

How Long Should We Continue Esketamine?

February 1, 2025

Steven Hamilton, PhD, MD

Steven Hamilton, MD, PhD. The Permanente Medical Group, Department of Psychiatry, Kaiser Permanente San Francisco Medical Center.

Dr. Hamilton has no financial relationships with companies related to this material.

Response to esketamine (Spravato) is brisk and bold, but how do you keep patients well over the long term? We look at new research on continuation, tapering, and switching strategies.

Clinical Update

Deep Rivers Run Quiet. An Update on Social Anxiety Disorder

March 8, 2023

Steven Hamilton, PhD, MD

Steven Hamilton, MD, PhD. The Permanente Medical Group, Department of Psychiatry, Kaiser Permanente San Francisco Medical Center. Dr. Hamilton has no financial relationships with companies related to this material.

SSRIs and CBT treat social anxiety disorder, but what do you do when they don’t work? Steven Hamilton describes 5 other pharmacotherapy options and shows us how to distinguish social anxiety from normal shyness.

The Uses of Pharmacogenetic Testing

October 1, 2014

Steven Hamilton, PhD, MD

Steven Hamilton, PhD, MD.

Psychiatrist, The Permanente Medical Group, Kaiser-Permanente San Francisco Medical Center, Clinical faculty, Department of Psychiatry, University of California, San Francisco.

Dr. Hamilton has disclosed that he is an unpaid scientific advisor to 23andMe, which offers a commercial genome test. Dr. Balt has reviewed this interview and found no evidence of bias in this educational activity.

Get insight into the uses of pharmacogenetic testing in psychiatry, in an interview with psychiatrist Steven Hamilton, MD, PhD.